Altered Heterogeneity of Ageing Lung Endothelium is a Hallmark of Idiopathic Pulmonary Fibrosis

Eamon C. Faulkner; Adam A. Moverley; Simon P. Hart; Leonid L. Nikitenko

doi:10.1101/2022.03.08.22272025

Abstract

Background Older age is the main risk factor for chronic lung diseases including idiopathic pulmonary fibrosis (IPF). Halting or reversing progression of IPF remains an unmet clinical need due to limited knowledge of underlying mechanisms. The lung circulatory system, composed of blood (pulmonary and bronchial) and lymphatic vessels networks, has been implicated in IPF pathophysiology in elderly people, based solely on reports of altered density and increased permeability of vessels.

Aim We aimed to define heterogeneity and IPF-associated changes of lung endothelial cells (EC or endothelium) by comparing gene expression in tissues from elderly people - transplant donors and recipients with IPF.

Methods Single-cell RNA sequencing (scRNAseq) datasets of “ageing lung” tissues were selected only from those publicly available sources that contain age-matching samples for both groups (49- 77 years old donors and IPF patients; nine pairs in total), integrated and compared. Findings were validated by immunohistochemistry using EC-specific markers.

Results The generation of integrated single-cell maps of ageing lung tissues revealed 17 subpopulations of endothelium (12 for blood and 5 for lymphatic vessels, including 9 novel), with distinct transcriptional profiles. In IPF lung, the heterogeneity of ageing lung endothelium was significantly altered - both in terms of cell numbers (linked to disease- related changes in tissue composition) and differentially expressed genes (associated with fibrosis, inflammation, differentiation and vasodilation) in individual pulmonary, bronchial and lymphatic EC subpopulations.

Conclusions These findings reveal underappreciated extent of heterogeneity and IPF-associated changes of ageing lung endothelium. Our data suggest direct involvement of specific subpopulations of ageing lung endothelium in IPF pathophysiology, uncovering cellular and molecular targets which may have potential diagnostic, prognostic and therapeutic relevance. This study creates a conceptual framework for appreciating the disease-specific heterogeneity of ageing lung endothelium as a hallmark of IPF.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The work is funded by Kate Garthwaite Pulmonary Fibrosis Research Fund, the University of Hull Endothelial Cell Research Fund, PhD Scholarships Fund for 'Health Global Data Pipeline (Health*GDP) for biomedical research and clinical applications' cluster and The Anatomical Society.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IPF samples and age-matched donor samples in cohort 1 were selected from the gene expression omnibus (GEO) GSE122960_RAW and in cohort 2 - from GSE136831_RAW

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

↵* These authors share senior authorship.
1). Previously presented figures have been updated. More specifically, in Figure 2D, novel genes in the signatures have been coloured in red. Furthermore, in Figure 3C and D, subpopulations with statistically significant differences in cell numbers between donor and fibrosis groups have been marked with an asterisk. Also, in Figure 4, the signature specificity ridgeplot and table have been moved to the Supplementary Material. Finally, Figure 5 has been renumbered as Figure 7, due to introduction of three new figures (see below). 2). New figures have been introduced to validate the scRNAseq findings by using immunohistochemistry and IPF biopsy. This includes Figures 5, 6 and 8. More specifically, Figures 5 and 6 contain new data on scRNA seq data analysis, immunostaining and high content imaging quantification for CLR and CD31. Next, Figure 8 includes lymphatic endothelial cell data which has been relocated from the Supplementary Data and also new data on immunostaining and high content imaging quantification for podoplanin. 3). Supplemental files have been updated by providing additional graphs for 5 of the previous figures and including 5 new figures and one table. 4). The main text has been updated to reflect the above mentioned changes, improve clarity of expression, update section titles (e.g. Integrated Single-Cell RNA Sequencing Analysis Reveals Endothelial Cell Contribution to Ageing Human Lung Tissue Microenvironment in IPF has been updated to Integrated Single Cell Map of Ageing Human Lungs Displays Endothelial Cell Contribution in Disease). Also, two new sections have been added to the text to describe new data presented in Figures 5 and 6 (see above). Furthermore, additional details have been provided to the description of findings on lymphatic endothelium - to reflect new data and relevant relocations from the Supplementary Material (see above). Finally, new sub-sections have been included in Methods section to reflect new experimental procedures which were used for generating data presented in Figures 5, 6 and 8. 5). Author affiliations have been updated to reflect recent changes.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

bioRxiv and medRxiv thank the following for their generous financial support:

The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.

Comments

medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our Comment Policy before commenting. The content of a comment is not endorsed by medRxiv.

Community Reviews

medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors.

Community reviews for this article:

There are no community reviews for this paper.

Automated Evaluations

Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv.

Automated Evaluations:

There are no automated evaluations for this paper.

Altered Heterogeneity of Ageing Lung Endothelium is a Hallmark of Idiopathic Pulmonary Fibrosis